Identification of the primary site of origin is an import first step but may not be sufficient 
available from the TCGA project. Our predictors were trained for 33 cancer types and for the 11
INTRODUCTION 64
Precision cancer therapy requires the knowledge of tissue of origin and accurate subtyping of expression profiles between CUPs and a set of primary and metastatic tumors with known of any tumor using in total 1,959 samples. Subtype classifiers achieved median sensitivity of 
141
(GEO) and the patient-derived xenograft (PDX) mouse models generated at the Jackson from their metastatic sites [36] . We used 88 of these tumors whose primary sites could be the expression profile of 338 PDX RNA-seq samples generated at the Jackson Laboratory and 153 available through the Mouse Tumor Biology (MTB) gene expression portal
154
(http://tumor.informatics.jax.org) [37] . Of these 338 samples, 325 samples could be mapped to 155 one of the 33 TCGA primary cancer types and the 7 OV samples were excluded as they 156 originate from the same two patients. The distribution of the primary types in the external 
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The DLDA classifier belongs to the family of Naive Bayes classifiers, where the distribution of 210 each class is assumed to be a multivariate normal and to share a common covariance matrix.
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The DLDA classifier is a modification to LDA, where the off-diagonal elements of the pooled sample covariance matrix are set to zero [47] . 
250
All models were trained using the same feature selection and cross-validation schedule. Each 
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RESULTS 292
Precise classification of primary cancer types across platforms
293
The classification of the 33 primary cancer types from the TCGA cohort (9,642 samples) by 294 random forest is presented in Figure 2A . Classification yields a median sensitivity and 
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To understand these misclassifications, the expression profiles of every training sample was primary tumor type, shown in Figure 3 
370
We further validate our classifiers independently using an external dataset from patient-derived 371 xenograft (PDX) models of cancer. PDX models of cancer are a great resource to evaluate 372 therapeutic regimens but can also be used as a tool to study metastatic cancer, as illustrated in 
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Eleven models were constructed, one model for each primary tumor type, into its molecular 398 subtypes, as illustrated schematically in Figure 1 . The positive predictive value, sensitivity, 399 specificity, and number of samples per subtype are shown in Figure 7A- 
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We developed classifiers of high sensitivity and specificity for prediction of tissue of origin of 33 457 cancers and molecular subtyping of 11 cancers using gene expression data from the TCGA. We 
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To circumvent this problem, in our future work, we will adopt a hierarchical classification of group. In addition, we can include features from copy number, mutation and methylation data to 475 augment our feature set for both accuracy as well as robustness for technology and batch 476 variations. Molecular subtyping can also benefit from adding features from heterogeneous data 477 as several subtypes were identified to exhibit genomic features that span whole spectrum of 478 omics data. For example, the CIN subtype in gastric cancer is known to exhibit large structural 479 variations which may not be captured accurately by expression data. Thus, our future work will 480 encompass comprehensive multi-omic data to identify tissue of origin and molecular subtyping.
482
Though the overall performance of the classifiers designed using DLDA, SVM and KNN is not 483 as good as Random Forest on this data, their performance is on par with or better than Random
484
Forest based classifiers on certain tumor type and subtype classification. However, the 485 classification predicted by Random Forest classifiers is easier to interpret.
487
As we continue to enhance the classifier, we do recognize that the clinical utility of the classifier 488 is dependent on its ability to classify FFPE (formalin-fixed paraffin-embedded) samples, which is 489 the standard specimen type used for molecular profiling of cancers in clinical diagnostics in 490 addition to fresh-frozen samples. We have previously shown that the classifiers designed can 491 work with FFPE samples if they are profiled using nanoString arrays [70] . Therefore, it is 492 feasible to generalize our classifiers to work on FFPE samples for clinical applications. In summary, we have demonstrated the utility of gene expression profiles to solve the important software, freely available for academic non-commercial use.
498
In an effort make these tools available to as wide an audience as possible, we offer our models 499 and results in two publicly available forms: a web-based portal and a software package which 500 can be used to apply these tools to other datasets and to reproduce the results presented 
FIGURE LEGENDS 529
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Expression profiles from all samples were embedded into two dimensions using uniform each cancer, labels are placed near the centroid of the expression profile in the UMAP latent 
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(D) Number of training samples for each molecular subtype. To further validate these subtype 589 classifiers, breast (E) and ovarian (F) subtype classifiers were used to predict the respective 590 molecular subtypes in two external datasets (GSE9899 and EGAS00000000083, respectively).
591
(G-H) Sensitivity and specificity for each classification in (E) and (F), respectively. 
